The Latest Cardiac and Vascular News
Caristo’s CaRi-Heart® AI Technology used to monitor effects of Orticumab detected a reduction in coronary inflammation and predicted a 50% reduction in risk of fatal cardiac events among patients with high coronary artery inflammation ATLANTA, April 8, 2024 /PRNewswire/ — Abcentra LLC, a…
Poster Presentation Details Visualization of Low-Voltage ECGs Hidden by Ablation Energy Artifact COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ — CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System’s predictive noise filter to increase…
New data support the feasibility of machine learned algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP) Data collected using the CorVista System®, the world’s first non-invasive point-of-care solution approved for evaluating the presence of coronary artery disease and pulmonary hypertension April 07, 2024 09:00 AM Eastern Daylight Time BETHESDA, […]
– In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in…
Basel, April 6, 2024 – Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone1. The late-breaking data were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology.
— Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels — — Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –
Results presented at ACC.24 showed that overall neutral results were due to directionally opposite effects in patients with reduced vs. preserved left ventricular ejection fraction Heart failure patients with reduced ejection (HFrEF) had 45% fewer adverse cardiovascular events, whereas…
April 05, 2024 06:31 AM Eastern Daylight Time NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 […]
SAN FRANCISCO, April 4, 2024 – Osso VR, the leader in immersive procedural training, announces the release of a co-developed curriculum with the American College of Cardiology (ACC). This collaboration expands Osso VR’s presence in the cardiovascular sector. With the integration of Osso VR’s immersive technology and the expertise of […]
